Dapagliflozin has FDA approved HF benefit while Empagliflozin has FDA approved CVD benefit. Dapagliflozin should be discontinued if eGFR falls below 60ml/min/1.73m² while Empagliflozin has a more wider renal safety window and can be given until eGFR falls below 45ml/min/1.73m². Empagliflozin has slightly higher reduction in HbA1c as compared to Dapagliflozin. 

Dapagliflozin is a non-selective SGLT-2 inhibitor. Empagliflozin is 5000 times more SGLT-2 selective than dapagliflozin. Since SGLT-1 receptors are present in the heart, dapagliflozin is more effective in patients with heart failure.